Federated Hermes Inc. Reduces Stock Holdings in Hims & Hers Health, Inc. $HIMS

Federated Hermes Inc. reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 79.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,802 shares of the company’s stock after selling 68,542 shares during the quarter. Federated Hermes Inc.’s holdings in Hims & Hers Health were worth $1,010,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Ethic Inc. purchased a new position in shares of Hims & Hers Health in the second quarter valued at $348,000. Steadview Capital Management LLC increased its holdings in Hims & Hers Health by 80.0% during the 3rd quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after acquiring an additional 311,845 shares in the last quarter. Carnegie Investment Counsel raised its position in Hims & Hers Health by 25.4% during the third quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock worth $17,238,000 after acquiring an additional 61,560 shares during the last quarter. Intellectus Partners LLC purchased a new stake in shares of Hims & Hers Health in the second quarter valued at about $3,043,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Hims & Hers Health in the third quarter valued at approximately $10,397,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 9,067 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78. Following the completion of the sale, the chief financial officer directly owned 91,617 shares in the company, valued at $2,779,659.78. This represents a 9.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares in the company, valued at $11,202,460.31. This represents a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 131,974 shares of company stock worth $4,763,800. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: HIMS is expanding its care stack by adding multicancer screening (Grail’s Galleri) to its platform, which can increase revenue per patient and strengthen its diagnostics-to-care ecosystem. Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
• Positive Sentiment: Analysts note HIMS is scaling a platform-led digital healthcare model (Labs, AI, YourBio Health) that could lift margins and stickiness if execution continues. Hims & Hers Strengthens Platform-Led Digital Healthcare Model
• Neutral Sentiment: Market response has been volatile: initial share gains after the $49 semaglutide reveal were followed by declines as legal and regulatory reactions emerged; expect elevated volume and short-term price swings. Hims’ $49 weight-loss pill rattles investor case for cash-pay obesity market
• Negative Sentiment: Novo Nordisk has publicly accused HIMS of illegal mass compounding and has vowed legal action, creating litigation risk, potential injunctions, and reputation/partnership fallout. Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding’ Over Cheaper Wegovy Version
• Negative Sentiment: The FDA’s leadership signaled potential enforcement against mass-marketed copycat drugs, raising regulatory risk that could limit HIMS’s ability to sell compounded GLP‑1s at scale. FDA’s Makary pledges crackdown on mass marketing of ‘illegal copycat drugs’
• Negative Sentiment: Broader market impact: major pharma peers (Novo, Eli Lilly) saw share moves tied to the story, and investors are weighing potential costly legal fights, regulatory scrutiny, and patient-safety scrutiny that could blunt near-term revenue from the pill initiative. Hims & Hers falls after Novo’s legal threat

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Barclays began coverage on Hims & Hers Health in a research note on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price on the stock. KeyCorp assumed coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating on the stock. Leerink Partners raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Finally, Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $42.62.

Hims & Hers Health Price Performance

HIMS opened at $23.02 on Friday. Hims & Hers Health, Inc. has a 1 year low of $21.12 and a 1 year high of $72.98. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The company’s 50 day simple moving average is $32.96 and its 200 day simple moving average is $43.47. The stock has a market capitalization of $5.24 billion, a PE ratio of 42.63, a P/E/G ratio of 3.87 and a beta of 2.43.

Hims & Hers Health announced that its board has initiated a stock repurchase program on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.